Wenyi Y. Lu

No. 24 Fu Kang Road
Tianjin, 300192, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 48 publications

Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma

Clinical and genetic characteristics of patients with mucosa-associated lymphoid tissue lymphoma transformed into diffuse large B-cell lymphoma

Journal: Zhonghua yi xue za zhi

Published: May 07, 2026

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax.

Efficacy analysis of CAR-T cells against CD123-positive malignant tumors and exploration of the feasibility of combination therapy with venetoclax.

Journal: Annals of hematology

Published: March 30, 2026

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Updated data of CLL1 CAR-T cell therapy in adult patients with relapsed/refractory acute myeloid leukemia.

Journal: Journal of hematology & oncology

Published: September 02, 2025

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation.

Journal: Frontiers in immunology

Published: September 04, 2024

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia.

Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy: A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia.

Journal: Chinese medical journal

Published: May 07, 2024

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia.

Chimeric antigen receptor T cells targeting CD312 as a therapy for acute myeloid leukemia.

Journal: Chinese medical journal

Published: May 05, 2024

Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma.

Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma.

Journal: Current cancer drug targets

Published: February 09, 2024

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia.

Journal: Cancer immunology, immunotherapy : CII

Published: January 12, 2024

Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.

Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation.

Journal: Leukemia

Published: December 07, 2023

Exploring sustainable food packaging: Nanocellulose composite films with enhanced mechanical strength, antibacterial performance, and biodegradability.

Exploring sustainable food packaging: Nanocellulose composite films with enhanced mechanical strength, antibacterial performance, and biodegradability.

Journal: International journal of biological macromolecules

Published: November 08, 2023

Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.

Developing Strategies to Improve the Efficacy of CAR-T Therapy for Acute Myeloid Leukemia.

Journal: Current treatment options in oncology

Published: September 13, 2023

CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.

CD22-targeted glyco-engineered natural killer cells offer a further treatment option for B-cell acute lymphoblastic leukemia.

Journal: Haematologica

Published: September 04, 2023

Showing 1-12 of 48

Last Updated: 09/26/2026